Aravive Inc (NASDAQ:ARAV) saw a large decrease in short interest during the month of June. As of June 30th, there was short interest totalling 20,700 shares, a decrease of 13.8% from the May 30th total of 24,000 shares. Based on an average trading volume of 15,100 shares, the short-interest ratio is presently 1.4 days. Currently, 0.4% of the company’s stock are sold short.
A number of equities research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. Wedbush set a $269.00 target price on shares of United Therapeutics and gave the stock a “buy” rating in a report on Monday, April 8th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Finally, Piper Jaffray Companies upped their target price on shares of Boot Barn from $33.00 to $41.00 and gave the stock an “overweight” rating in a report on Monday, May 13th.
ARAV opened at $5.90 on Friday. The company has a current ratio of 7.78, a quick ratio of 7.78 and a debt-to-equity ratio of 0.17. Aravive has a fifty-two week low of $3.07 and a fifty-two week high of $12.60. The stock has a 50-day simple moving average of $5.93.
Hedge funds have recently modified their holdings of the business. Northern Trust Corp bought a new stake in Aravive in the 4th quarter worth about $54,000. California Public Employees Retirement System bought a new stake in Aravive in the 4th quarter worth about $57,000. Acadian Asset Management LLC bought a new stake in Aravive in the 4th quarter worth about $60,000. D. E. Shaw & Co. Inc. bought a new stake in Aravive in the 4th quarter worth about $73,000. Finally, Deutsche Bank AG bought a new stake in Aravive in the 4th quarter worth about $78,000. 27.57% of the stock is owned by institutional investors and hedge funds.
Aravive Company Profile
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Read More: Price-Sales Ratio
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.